Posted on

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Published at newswire.ca

‍

DENVER, Jan. 14, 2021 /CNW/ – Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity” or the “Underwriter”), pursuant to which Canaccord Genuity has agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 20,000,000 units of the Company (the “Units”) at a price of C$0.50 per Unit (the “Issue Price”) for aggregate gross proceeds to the Company of C$10,000,000 (the “Offering”).

Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will be exercisable to acquire one Common Share (a “Warrant Share”) for a period of 36 months following the Closing Date at an exercise price of $0.70 per Warrant Share.

The Company has granted the Underwriter an option (the “Over-Allotment Option”) to purchase up to an additional 3,000,000 Units at the Issue Price for a period of 30 days following the Closing. If the Over-Allotment Option is exercised in its entirety, the aggregate gross proceeds of the Offering will be C$11,500,000.

The Company plans to use the net proceeds of the Offering to invest in additional clinical trials, for expansion of its intellectual property portfolio, continued development of its drug pipeline, expanded research and development partnerships and initiatives and for general working capital purposes.

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on February 3, 2021 (the “Closing Date”), and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities. The Company will use best efforts to obtain the necessary approvals to list the Common Shares and the Warrants on the Canadian Securities Exchange.

The Underwriter shall be paid a cash commission equal to 7.0% of the aggregate gross proceeds of the Offering payable in cash or Units, or any combination of cash or Units at the option of the Underwriter, and warrants (the “Underwriter’s Warrants”) exercisable at any time prior to the date that is 36 months from the Closing Date to acquire that number of Units which is equal to 7.0% of the aggregate number of Units issued pursuant to the Offering, at an exercise price equal to the Issue Price. Additionally, the Company shall pay the Underwriter a corporate finance fee equal to that number of Units which is equal to 2.5% of the aggregate number of Units issued pursuant to the Offering.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Mydecine Innovations Group
Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions, and which may include, but are not limited to, statements with respect to the expected Closing date of the Offering, the listing of the Common Shares and Warrant Shares on the Canadian Securities Exchange, the use of proceeds of the Offering, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVD-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

‍

Posted on

Researchers will soon test psychosubstances as a potential treatment for veterans with PTSD.

Published at HCPLive.com

‍

HCPLive® – Play Video

There always is some level of trial and error in finding the correct treatment for patients suffering post-traumatic stress disorder (PTSD).

Often patients can go through multiple iterations before finding the right treatment option, highlighting the need to expand the treatment pool.

One potential option could be psychosubstances.

In a new study, researchers are testing low-dose psychosubstances to treat veterans with PTSD, believing psychedelic substances could help these patients manage some of their symptoms of depression and anxiety.

In an interview with HCPLive®, Rakesh Jetly, MD, Head of the Center of Excellence on Mental Health, explained the parameters of the phase 2 study and how he believes the research is on the cutting edge of a breakthrough treating trauma.

He said a major problem in PTSD and psychiatry in general is the amount of patients who do not respond to first line treatments, taking valuable treatment time finding the correct medication. He said approximately half of this patient group does not respond to first-line therapies.

Jetly, who is a military psychiatrist, has committed to finding evidence-based treatments for combat veterans early in his career, but within the last decade has begun to think out of the box for other treatments.

‍

Posted on

Mydecine Innovations Group Uniquely Positioned To Take Over 2021

Published at Microdose.com

‍

Obstacles That Mydecine Overcame This Previous Year

2020 was both a phenomenal and challenging year for the psychedelic renaissance. In terms of sheer popularity, there is no question that psychedelic medicine has perked the ears of the public. This shift in attitude towards these powerful psychoactive compounds is reflected in our popular media, and likewise, the activity of investors at large. Headlines pertaining to the use of psychedelics to treat PTSD, for example, indisputably put the spotlight on innovative psychedelic biopharma company Mydecine Innovations Group (CSE: MYCO).

Mydecine not only had a successful year, but an important year, considering the company’s ability to accomplish things that have never been done before in this nascent industry. Indeed, Mydecine was first to get CGMP status to produce/sell/export medical psilocybin. Similarly, the life science company was first to execute a legal import and export of psilocybin mushrooms. But this is not to say that the company did not face difficulties.

According to Josh Bartch, CEO and Director at Mydecine, the psychedelic industry faced struggles in the same manner than all industries did in 2020 amid a public health crisis. “As you would expect, our number one hurdle was dealing with the unprecedented global pandemic which has temporarily hindered some of the progress with in-person clinical studies,” said Bartch. “With that said, we have introduced tools such as our digital telehealth platform, Mindleap Health, for patients and specialists to connect remotely to find innovative solutions which allow patients and specialists to connect remotely.”

Given that Mydecine was able to navigate this previous year, teaming with the University of Alberta to push the overton window of what is possible in psychedelic R&D, then surely they will be an even greater force to reckon with this year.

Want to learn more about Mindleap? Stream our PsyFi episode with Nikolai Vassev, Founder of Mindlep Health. The PsyFi podcast is available on YouTube, Spotify, and Apple Podcasts.

mydecine innovations group psychedelic medicine new research

Mydecine is at a Significant Advantage Market-Wise

Clinical prowess is at the core of the excitement surrounding Mydecine, but from an investor’s standpoint, we ought to discuss Mydecine’s position marketwise. The company has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze psychoactive mushroom compounds. More importantly, Mydecine does so with full government approval through Health Canada – making them inherently a key player in the emerging psychedelic market.

Clearly, the company is not tied down to any one specific goal. For example, the company’s acquisition of Mindleap – a digital platform and mobile app that connects patients to psychedelic therapy/specialists – makes them valuable in both medicinal and technological markets. Furthermore, the accessibility of the app will likely draw in the average interested consumer, making psychedelics less of a niche interest and more of a groundbreaking treatment for the masses. The app brings the entire industry forward in this regard. Mydecine is also pursuing the R&D of non-psychedelic medicinal mushrooms, and this additional facet of diversified revenue adds to their investor appeal.

mydecine innovations group psychedelic medicine new research

The Clinical Efforts that Separate Mydecine from Other Companies

Psychedelic enthusiasts will recall that during the tail end of 2020, Mydecine announced that it has engaged Ethica CRO as a partner for their Phase 2A PTSD clinical trials. This brings society closer to helping the long neglected psychological needs of war veterans and EMS/frontline workers. Moreover, these trials are international (taking place at Leiden University Medical Centre in the Netherlands, the University of Western Ontario, and the University of Alberta), which means the aforementioned neglected demographics will be helped all across the globe. Mydecine has other clinical sites on the horizon in the USA, Europe, and Australia, too.

Furthermore, Mydecine’s SAB member Dr. David Erritzoe helped execute a large-scale microdosing study co-sponsored by the National Institute for Health Research at Imperial College of London (a name that should ring a bell for readers in the psychedelic medicine community). Similarly, Mydecine was involved with a first-of-its-kind Microdose study at Mcquery University in Australia. Though Mydecine is perhaps best known for their noble efforts to treat PTSD, we can expect Mydecine to tackle many indications with this level of clinical ambition (e.g., psychedelic-assisted therapy in treatment of substance use disorder).

With that being said, Mydecine is able to take on these projects with a clear advantage specific to only them: the ability to isolate compounds no one else has their hands on yet thanks to their collaboration with the University of Alberta. Mydecine filed seven patent applications to further explore the medicinal properties of mushrooms.

Curious how psychedelics can be utilized in the treatment of PTSD? Check out our PsyFi episode with Colonel Rakesh Jetly, MD, the senior advisor in Psychiatry for the Canadian Armed Forces and Head of the Centre of Excellence on Mental Health. Our PsyFi podcast can be found on YouTube, Spotify, and Apple Podcasts.

mydecine innovations group psychedelic medicine new research

Mydecine Will Continue to Thrive in 2021

A capital markets analyst at Canaccord Genuity Group, one of the most prominent investment banks in psychedelic medicine, recently estimated that the psychedelic market will be worth nearly $100 billion. With recent decriminalization/legalization efforts surrounding psilocybin, the market is in a great position. It should be no surprise that Mydecine was listed as one of the “top psychedelic firms to watch” in the publication of this analyst’s estimate. Mydecine is uniquely positioned to thrive in 2021.

Moreover, Mydecine’s successes to come are good for society at large. We mustn’t forget that the company’s over encompassing goal is to alleviate mental health crisis, which is particularly important after the rough year we all shared. There is no doubt that Mydecine will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply.

‍

Posted on

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

Published at Real Money

By Debra Borchardt

‍

Stocks quotes in this article: CMPS, MMEDF, CLXPF, MYCOF, CGC

With so many new IPOs and companies launching in the psychedelic industry it’s important to fully evaluate the major factors of success or failure in the industry. There are various steps that companies take to have a drug approved and to successfully complete them it takes years and tens of millions of dollars. The further ahead a company moves in the approval process, the more valuable the company becomes, and that is why there is so much excitement for Compass Pathways (CMPS) . Institutional and retail investors are in a frenzy to get a position. The company is in Phase 2b and has received a “Breakthrough Therapy” designation from the FDA, meaning that their therapy has the potential to be more effective than available medications.

Currently there are only a handful of companies that have:

  • Access to psychedelic compounds
  • A clear idea of the disorder they are targeting, also known as drug indication
  • Are actively running a clinical trial.

It’s important for investors to be mindful of the stage a company is in and to fully evaluate if a company they are investing in has the potential to be successful.

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine (MMEDF) , Cybin Inc. (CLXPF)  , and Mydecine Innovations Group (MYCOF) . Here’s an analysis of these biotech players and we highlight the most undervalued company in the industry.

What is the Drug Discovery Process?

The drug development process being undertaken is to ensure these treatments are safe and effective for consumption.

  1. The drug is investigated and screened tested on animals to prove safety (can be skipped since psilocybin has been proven safe and effective)
  2. Investigational drug application to FDA and Health Canada is submitted that includes, drug composition, formulation and manufacturing process
  3. Clinical Trial Plan including selection of location
  4. Recruitment of volunteers
  5. Analysis of findings and submission
  6. Approved to move to next Phase in larger population

Psychedelic Companies with Phase 2 Trials Valuation Comparison

Biotechnology companies are hard to value as it’s hard to predict success of clinical trials. Biotech companies are unique types of investments that can either pay off handsomely or end with a complete loss of capital. One of the best ways to value a company is by looking at the size of the addressable market and estimating the potential market penetration.

The reason Compass Pathways is leading the charge in psychedelics is they have a drug that is more effective than anything available, has a total addressable market of 16 million adults, and can upend this entire market as a whole.

What key parameters to look for valuing biotech companies?

  1. Experienced Science team
  2. Experienced Management Team
  3. Intellectual property protection
  4. Large addressable market
  5. Potential Market Penetration Possible
  6. Access to patients
  7. Access to active ingredients
  8. Unique R&D Capabilities
  9. Scientific Community Collaborations

Compass Pathways

COMPASS Pathwaysoperates as a mental health care company in the UK and the U.S. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company is currently the most valuable and most well-known company in the industry and has raised over $250 million since its inception.

Current Market Cap: $1.57 Billion

Drug in development: COMP360 Psilocybin for Depression

Indication: Treatment Resistant Depression

Total Addressable Market: $1.12 billion by 2024

Stage: Phase 2B

Location: Multiple sites globally

Mind Medicine Inc.

Mind Medicine, also known as MindMed, is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for adult ADHD. The company has also added MDMA to its R&D pipeline to explore MDMA’s potential to treat mental health disorders.

Current Market Cap: $977 Million

Drugs in development: LSD for Adult ADHD, LSD for Suicide Headaches, Ibogaine for Addiction

Indication: Various

Total Addressable Market: Unknown but the largest of all studied companies

Stage: Phase 2a

Location: Multiple sites globally

Cybin Inc.

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Current Market Cap: $203 Million

Drug in development: Sublingual Psilocybin Delivery Mechanism for Depression

Indication: Major Depressive Disorder

Total Addressable Market: $5.8 billion by 2025

Stage: Phase 2 A

Location: University of West Indies Jamaica

Mydecine Innovations Group

Mydecine Innovations Group is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing well-being. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.

Mydecine was the first company to offer CGMP naturally sourced psilocybin and recently made history again by making the first legal export of Magic Mushrooms. Mydecine has a big focus on intellectual property and is utilizing genome technology (editing plants like what GW Pharma did in Cannabis) under the leadership of Rob Roscow the ex-Canopy Growth (CGC) head of genetics and at Mydecine’s U.S. and Canadian laboratories. The company now has over 20 kilos of psilocybin mushrooms – most in the industry – and has active ingredients for their trials at a fraction of the cost that Compass Pathways or Cybin ever can with their synthetic drugs.

Current Market Cap: $56 Million

Drug in development: Naturally Sourced Psilocybin

Indication: PTSD

Total Addressable Market: $10.6 B by 2026

Stage: Phase 2 A

Location: Multiple Sites Globally

As illustrated above, by making side by side comparisons of companies that are in Phase 2 trial studies, investors can quickly see the size of the addressable audience and the market cap of the company. This makes it easier to see if there is a stock that might have more room for upside than others. As the focus on psychedelic stocks increases, so do the valuations. There is concern that some company valuations have gotten ahead of themselves and investors may want to take that into consideration before hitting the buy button.

Posted on

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined the Company as Chief Financial Officer.

“MYCO continues to augment its C-Suite and board of directors with key independent, professional members to provide oversight into our governance policy to meet anticipated capital markets initiatives slated for this year,” said Josh Bartch, Chairman & CEO of Mydecine. “MYCO welcomes capital markets and governance veteran, Gordon Neal, as an independent director who, with his many years of board, board committee, and oversight experience will be invaluable in our corporate deliverables. Likewise, the addition of Dean Ditto as CFO will contribute to the Company’s commitment of strengthening internal controls, audit oversight and risk mitigation. His tenure with a Big 4 public accountant firm combined with 20 years of financial leadership makes him an added asset to our C-Suite team.”

“I thoroughly believe in the potential of psychedelic-assisted psychotherapy and I’m honored to have this opportunity to help Mydecine’s team be successful in the company’s future product commercialization efforts,” said Mr. Neal. “Over the years, as the founder of Neal McInerney Investor Relations, I was involved in marketing more than $4 billion in debt and equity financings as well as providing capital market strategies to multi-national companies and my passion for bringing innovative new therapies to the market for patients perfectly aligns with Mydecine’s mission as a global leader in the psychedelic space.”

“I have a profound belief in Mydecine’s vision and mission,” said Mr. Ditto. “The Company’s commitment to developing treatments for veterans and others suffering from PTSD has resonated deeply with me. I look forward to working with the entire team to help shape the future of the Company.”

About Gordon Neal

Gordon Neal has more than 35 years’ experience in governance, corporate finance and investor relations. He founded Neal McInerney Investor Relations in 1991. Through marketing more than $4 billion in debt and equity financings, his company grew to be the second largest full-service Investor Relations firm in Canada with offices in Vancouver, Toronto and Los Angeles. His clients included; BCE, Nortel, Bell Canada International, Bell Mobility, Clearnet, Intrawest, Canaccord Capital, BMO Nesbitt Burns, and Blackberry (RIM). Prior to that, Mr. Neal was VP Corporate Development at MAG Silver Corp. where he provided capital market strategies and solutions to the board. He is currently the President of New Pacific Metals Corp. Mr. Neal has served on the boards of Falco Resources, Balmoral Resources, Americas Petrogas, Rockgate Capital, and Xiana Mining. Mr. Neal has raised more than $500 million for resources companies since 2004. Mr. Neal graduated from Dalhousie University with a B.Sc. in Biochemistry. He has also served as a member of the Dalhousie University Senate and Board of Governors.

About Dean Ditto

Dean Ditto is an experienced CFO who has helped middle market companies elevate the financial function, secure capital, drive growth and improve profits. He joins Mydecine from Sigue Corporation where he served as CFO and was responsible for leading the finance team in business planning, budgeting, financial analysis and accounting. In addition, he was a Big 4 public accountant at PricewaterhouseCoopers before progressing to leadership roles with increased responsibilities, including C-suite and corporate officer roles. His areas of expertise include SEC reporting, treasury, internal audit, controls, tax, risk management, compensation planning, facilities, vendor programs, payroll and 401k. His key accomplishments include leading a financial services company through a business turnaround that improved annual profits by $15 million through managing costs, restructuring debt, and discontinuing unprofitable operations. Mr. Ditto’s professional certifications include Certified Public Accountant and Certified Internal Auditor and he earned his MBA degree from the Kelley School of Business, Indiana University.

About Mydecine Innovations Group
Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

‍

Posted on

Further Research into Psilocybin Opens New Doors for Treatment

Published at PRNewsWire.com.

‍

NEW YORK, Jan. 7, 2021 /PRNewswire/ — Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others. In addition, new segments under the biotech umbrella are constantly being developed. For example, the medical cannabis segment has rapidly emerged in recent years, and the continuously growing acceptance of psychedelic drugs is further evidence. The perceptions about psychedelics and their possible uses have also started to shift from a potentially dangerous party drug to an approachable medicinal product. For example, earlier in 2019, the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine) a nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant. Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Mydecine Innovations Group Inc. (OTC: MYCOF) (CSE: MYCO), Eli Lilly and Company (NYSE: LLY), Revive Therapeutics Ltd. (OTC: RVVTF), Hollister Biosciences Inc. (OTC: HSTRF), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

James Kuo, the CEO and co-founder of California-based Tryp Therapeutics, explained, according to a report by Forbes, that while psilocybin remains among the most restricted drugs in North America, recent changes in regulations are enabling more clinical research and trials of the substance to be carried out. “These substances [including psilocybin] will become more available with their safety being demonstrated over time … Over-the-counter happened with some of the older medications — they were initially available at drugstores for prescriptions only… but I think people with very specific medical problems, such as pain or eating disorders, will be the most likely to adopt the type of functional food with psychiatric care components.”

Mydecine Innovations Group Inc. (OTC: MYCOF) (CSE: MYCO) announced earlier this week that, “it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University

The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.

‘Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,’ said Dr. Polito. ‘In exploring the experiences of genuine microdosers from multiple angles, looking at behavioural, neuroimaging and biomarker data, we want to discover what actually happens when people microdose ‘in the wild’ and whether we can find objective indicators of some of the benefits that microdosers claim.’

The study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.

‘This study will further shed light on currently ambiguous effects of microdosing,’ said Josh Bartch, CEO and Co-Founder of Mydecine. ‘Microdosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, we are helping to build a library of solid data sets that begin to tell us how microdosing works, and how it can be used in future clinical trials for various mental health issues.’

Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University. His focus is on self representation and developing measures of how our sense of self changes in different contexts, clinical conditions, and altered states of consciousness.”

To get more information on Mydecine Innovations Group Inc. please visit here.

Eli Lilly and Company (NYSE: LLY) is currently one of the largest manufacturers of psychiatric medications and produces Prozac (fluoxetine), Dolophine (methadone), Cymbalta (duloxetine), and Zyprexa (olanzapine). A recent study in mice led by UCLA biologists strongly suggests that serotonin and drugs that target serotonin, such as anti-depressants, can have a major effect on the gut’s microbiota — the 100 trillion or so bacteria and other microbes that live in the human body’s intestines. Serotonin — a neurotransmitter, or chemical messenger that sends messages among cells — serves many functions in the human body, including playing a role in emotions and happiness. An estimated 90% of the body’s serotonin is produced in the gut, where it influences gut immunity.  When mice were given the antidepressant fluoxetine, or Prozac, the biologists found this reduced the transport of serotonin into their cells. This bacterium, about which little is known, is called Turicibacter sanguinis.

Revive Therapeutics Ltd. (OTC: RVVTF) announced on November 18th, that it had entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation and a specialty psychedelics pharmaceutical company, to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds. “Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach,” said Michael Frank, CEO of Revive. “We are excited to advance the development of PharmaTher’s recent discovery in the potential of psilocybin to treat certain cancers such as Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia. We are also leveraging PharmaTher’s panaceAI™ discovery AI platform to discover new uses of undisclosed psychedelic compounds to be potentially used with our oral thin film delivery technology and expand our psychedelics drug pipeline.”

Hollister Biosciences Inc. (OTC: HSTRF) announced on June 4th, that the Company’s 100% owned subsidiary, AlphaMind Brands Inc. plans to launch medicinal mushroom based capsule and powder product lines.  The initial product line will consist of a blended and bottled powder and capsule consisting of powdered cordyceps, lion’s mane, oyster, reishi and shiitake medicinal mushroom varietals. The formulations for both products are unique and developed through research driven initiatives. The health benefits that the capsules and powder intend to provide include but are not limited to anti-inflammatory, antioxidant, anti-aging, anti-microbial and immune system support.  Dr. Nikos Apostolopoulos, CSO of AlphaMind shared, “Our AlphaMind five mushroom blend will be a game changer for both athletes and non-athletes alike. This ethically sourced and organically grown blend provides potent antioxidants, and anti-inflammatory responses, helping to improve and maximize performance as well as daily activities.”

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. Last yeah, Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, outlined a new statistical method to analyze future Posttraumatic Stress Disorder (PTSD) drug studies and presented a retrospective analysis using the new method of the Phase 3 HONOR study (P301) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment of military-related PTSD. “The paradox that confounds modern PTSD studies is that the placebo response has increased over time, even as we and others have striven to improve study methods and data quality,” said Dr. Lederman.

‍

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com  (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. Clients from time-to-time place links in FinancilBuzz.com editorials and these are strictly for informational purposes only and FinancialBuzz.com has not researched these links and are not responsible for their content.  We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For mydecine innovations group inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by marketjar media inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

‍

Posted on

Mydecine Innovations Group Shares Intellectual Property Update

Published at GlobeNewsWire.com

‍

DENVER, Jan. 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the filing of seven provisional patent applications with the United States Patent and Trademark Office (USPTO) in its efforts to discover valuable novel compounds in fungi for medicinal and pharmaceutical use.

In an effort to better understand the medicinal properties of fungi-based compounds, Mydecine is developing novel intellectual property around medicinal mushrooms and psychedelic medicines for the professional healthcare market. Led by Chief Science Officer Rob Roscow, the developing patent portfolio from Mydecine is targeted at addressing the known shortcomings of psilocybin for medical uses and includes novel drug design and delivery mechanisms, precise doseable formulations and new technologies for improved use of psilocybin in a medical context.

“These patent filings serve as a significant milestone for Mydecine in our efforts to build a unique and proprietary intellectual property portfolio of pharmaceutical and natural health products that address the growing interest in fungi-based solutions,” said Josh Bartch, CEO of Mydecine. “We believe in the power and potential of these compounds to treat and provide incredible relief to those suffering from mental health issues and will continue forward with our research efforts to better understand how they work together to augment the mind and body in new and powerful ways.”

The Mydecine team believes, through its extensive in-house research and development efforts and robust partnerships with world-class research institutions and universities, that it has data-supported evidence of novel compounds in fungi that can be eventually applied to improve the properties of existing over-the-counter products and pharmaceuticals.

“By applying a distinct pharmaceutical chemistry approach in our research and development, we are well on our way to better understanding the key attributes and mechanisms of medicinal and psychedelic mushrooms that allow them to positively impact our thoughts, feelings, beliefs, and attitudes,” said Denton Hoyer, Ph. D and Mydecine Scientific Advisory Board Member. “As this valuable new natural product category continues to evolve, we believe there is great opportunity to use this knowledge to make a sustainable imprint on society and improve the overall health and wellbeing of all.”

About Mydecine Innovations Group
Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

‍

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

‍

Posted on

2020 Was A Year of Historic Firsts That Set the Stage for the Psychedelic Renaissance

Published at Microdose

‍

The world undoubtedly faced unforeseen challenges last year in the wake of the Coronavirus pandemic. However, we as a society also witnessed psychedelic medicine make unprecedented progress in 2020. From Mydecine’s first psilocybin extraction to Compass Pathways debuting on the NASDAQ, 2020 had no shortage of exciting developments on the psychedelic medicine front. Together, this massive progress has set the stage for the psychedelic renaissance with much more to come in 2021. Here is a list of all the historic firsts that psychedelic medicine had in 2020.

First Psychedelic

Mydecine Innovations Group Completed First Legal Psilocybin Extraction & International Export

The innovative team at Mydecine completed the first legal psilocybin extraction in 2020. They were also the first to export these mushrooms internationally. From the press release:

“[Myedecine has] completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import.”

This historic milestone sets an extraordinary precedent for psilocybin science and psychedelic medicine as a whole.

Mindleap Launches First Psychedelics Focused Telehealth Platform

The psychedelic renaissance is bringing forth an exciting new age of digital therapeutics and telehealth platforms. At the forefront of this movement is Mindleap Health, a subsidiary of the Myedicine group, that launched the world’s first telehealth platform for psychedelic integration.

From the press release:

“Mindleap was founded with the goal of enhancing the wellbeing of millions of people that struggle with mental health problems. By combining traditional telemedicine with mood and behavior analytics, the Mindleap platform offers a powerful set of tools for managing mental healthcare.”

The robust platform allows users to browse vetted and experienced specialists and easily schedule appointments and purchase mental health services.

There are benefits for the healthcare providers too. From the release:

“Specialists on Mindleap benefit from the platform’s full freedom to manage their virtual practice on their terms; setting their own prices and choosing the hours they work each week (with no minimums or maximums).”

As the psychedelic renaissance continues to progress, so will the diverse and robust arena of digital therapeutics. Such progress stands to benefit the entire field of healthcare, a promising thing to look forward to.

Compass Pathways’ Leads the Way as the First Psychedelics Company To IPO on the NASDAQ

Being the first psychedelic company to debut on the NASDAQ is a really big deal, and that’s exactly what the Peter Thiel-backed dynamo, Compass Pathways (ticker: CMPS), managed to do. The team at Compass listed a $100 million dollar IPO for psilocybin-based therapy. With millions of people suffering from depression across the globe, the team at Compass is poised to make a massive impact on mental health treatment with psilocybin therapy. Their debut on the NASDAQ sets a major precedent for psychedelic stocks and the emerging renaissance overall.

Field Trip Launched the First Psychedelics app & Opened Psychedelic-Enhanced Therapy Centers

The progressive team at Field Trip Health launched the first psychedelics app, Trip, that “allows people from anywhere in the world to access tools that support self-exploration and consciousness expansion through meditation, breathwork and more.” In addition to expanding their digital offerings, the progressive team at Field Trip also opened psychedelic-enhanced therapy centers in Canada and the United States. Their most recent center, which currently offers ketamine-assisted psychotherapy, opened up in Chicago, Illinois.

First Psychedelic

Mydecine Innovations Group Launched First Ever Psilocybin Clinical Trials with Veterans

Originally based out of Denver, Mydecine (CSE: MYCO) launched the first ever psilocybin-based clinical trials for treatment of war veteran PTSD. Indeed, after buying NeuroPharm Inc. in the summer of 2020, Mydecine went ahead to proceed with these clinical trials. The clinical trials also hoped to treat PTSD among EMS and first responders, and this noble effort reached Phase 2A of the clinical process. Those who have been in space for quite some time will recall that PTSD is usually coupled with subsequent depression and/or substance use disorder – which are also indications which psilocybin may treat effectively.

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

You read correctly – Mind Medicine (NEO: MMED), the leading psychedelic pharmaceutical company championed by Shark Tank’s Kevin O’Leary, announced the first ever clinical trial exploring the therapeutic benefits of combining MDMA and LSD. This combination, once dubbed as “candy flipping” in the underground psychedelic scene, is now being explored with clinical prowess for the first time. In the original announcement of this trial, MindMed explained that MDMA may negate the negative effects of LSD (or other classical psychedelics, for that matter). This move is quite genius considering that some of the unpleasant side effects of LSD (e.g., a considerably strange “come up,” subsequent panic, etc.) would be easily replaced by the well-studied euphoria induced by MDMA.

Psychedelic Pioneers at Numinus Team Up With MAPS to Conduct Groundbreaking MDMA-assisted Psychotherapy Trial for PTSD

The psychedelic pioneers at Numinus, one of the best known players in the space, teamed up with with MAPS last year and announced a collaboration agreement regarding an open-label trial of MDMA-assisted psychotherapy for PTSD. The dynamic psychedelic company also completed their first legal psilocybin harvest in October of 2020–another huge first for the team and the psychedelic renaissance overall.

You can learn more about the exciting developments from the Numinus team by checking out this PsyCap recap from their Psychedelic Capital presentation here.

Fireside Project, a San Francisco-based nonprofit organization, is launching a psychedelic peer support hotline — the first of its kind.

Though the news of psychedelic therapy advances is exhilarating and fun to watch, the actual psychedelic therapy sessions are quite challenging. Part of what makes psychedelics such a powerful adjunct to psychotherapy is their ability to bring difficult (but necessary for healing) conversations to the forefront of one’s psyche. Likewise, some can be especially off-put by induced hallucinatory effects. Luckily, the first ever psychedelic peer support hotline will be available to the public in 2021. Launched by Fireside Project, a San Francisco-based non profit, the hotline is meant to walk folks through these challenging and sometimes outright scary psychedelic experiences. This is a huge step up for the harm reduction movement, as psychedelic experiences are most powerful when done safely. The hotline (1-833-2FIRESIDE) is slated to begin April 14, 2021, and run 24/7. What a fantastic contribution to the modern drug user’s arsenal of safe protocols.

UK Company, Small Pharma, Secures Approval for World’s First DMT Clinical Trial

One of the larger firsts this previous year was one felt on an international level – the world’s first regulatory-approved patient clinical trial using N,N-dimethyltryptamine (DMT). Executed by UK neuropharmaceutical company Small Pharma, this announcement debuted Dec. 10, 2020. Like most companies in this space, their focus on psychedelics is in pursuit of alleviating clinical mental health symptoms. DMT has considerably shorter (and more controllable) duration than other psychedelics, which brings about unique therapeutic applications. This is partially why Canadian biotech company Entheon Biomedical is pursuing DMT in treatment of substance use disorder.

Mindmed is the First Psychedelic Company to Go Public & Trade on the NEO Exchange

After a fantastic pre-IPO round for MindMed, featuring the aforementioned Kevin O’Leary and also Bruce Linton (prolific investor and former CEO of Canopy Growth), the company became the first psychedelic organization to go public. Subsequently, MindMed started trading on the NEO exchange under the ticker symbol MMED. The company’s historic pre-IPO round raised a whopping $24 million (of course, we’d later see them reap in significantly more capital). Furthermore, upon being listed on the NEO exchange, MindMed sold over 14 million shares. It is precisely this kind of news that draws in more investors towards emerging psychedelic companies period.

Mindbloom is the First Company to do an “At Home” Virtual Ketamine Treatment

Amid a horrific heightening of the COVID-19 pandemic, NY-based mental health company MindBloom offered remote-enabled ketamine therapy to struggling homebound individuals. This is an especially important service for two reasons: first, the mental health crisis increased amongst U.S. citizens once social distancing (e.g., stay at home orders, consequential closing of workplaces) was implemented. Folks were stuck at home, and because of this, existing mental health symptoms were exacerbated which were otherwise regulated by a change of scenery and the comfort of in-person relationships. MindBloom’s ketamine therapy sessions helped such individuals. Second, existing in person mental health care facilities were no longer ethically able to have patients come in. Some of this nation’s most depressed members deeply depended on the care of a mental health professional, and in the face of losing that care, MindBloom provided a safe virtual alternative.

The Conscious Fund Launched the World’s First Psychedelic Job Board

Time and time again, the psychedelic community may subconsciously take the lesser discussed roles of psychedelic medicine for granted. Indeed, headlines consistently remind us of mover-shaker CEOs and investors in the space, but likewise, the industry runs thanks to the therapists, project managers, media associates and other employees of psychedelic medicine. The Conscious Fund (the leading global early-stage venture fund for psychedelics) helped many fulfill these roles in the summer of 2020, when they launched the world’s first psychedelic industry job board. The premise and usefulness of this job board is summarized perfectly in their initial announcement of the job board:

“Even with a global downturn, the psychedelic medicine industry is booming and creating an entirely new range of exciting opportunities and career paths across roles in science, manufacturing, finance, operations, and professional services. However, despite this exciting growth, we noticed there was an information gap between professionals looking to enter the space and companies looking to access global talent. We decided to fix that.”

The DPV Launched the World’s First Psychedelic Video Museum

Cleverly announced on April 16, the day Albert Hoffman first accidentally tripped on LSD, The Daily Psychedelic Video announced their launch of the world’s first psychedelic video museum. For those who missed it, Daily Psychedelic Video (DPV) has spent the last decade making and posting fantastic psychedelic visuals for the public to enjoy. They doubled down on this and created a psychedelic video museum, featuring 700 DPV videos and 45 different themed exhibits (e.g., sixties psychedelia, psychedelic activism, psychedelic hip hop, etc.). Readers are encouraged to check out the DPV museum ASAP, for it truly represents our juncture in time – the intersection of technology and psychedelia.

The University of Aukland Launched the World’s First Randomized Controlled Clinical Trial of LSD Microdosing

Despite the growing interest and positive testimonies regarding microdosing worldwide, the law still makes it quite difficult to study microdosing’s efficacy. But in 2020, the University of Aukland launched the world’s first randomized and controlled clinical trial pertaining to microdosed LSD. The trial involved 40 male volunteers who agreed to take sub psychedelic LSD dosage “every fourth morning” of their daily schedule. We ought to say thank you to psychedelic academic figures like Dr. Suresh Muthukumaraswamy for pioneering such studies, especially in New Zealand, where the drug has spent many decades as a strongly prohibited substance.

A Scientific First: How Psychedelics Bind to Key Brain Cell Receptor

For the first time, scientists solved the high-resolution structure of these compounds when they are actively bound to the 5-HT2A serotonin receptor on the surface of brain cells. This discovery is already leading to the exploration of more precise compounds that could eliminate hallucinations but still have strong therapeutic effects. Psilocybin – the psychedelic compound in mushrooms – has already been granted breakthrough status by the FDA to treat depression.

Oregon is First State to Legalize Psilocybin

Those who didn’t keep up with psychedelic industry news certainly heard about the following 2020 groundbreaking moment, as it pertains to cognitive liberty more broadly, and came at a time of high political tension. On Nov. 3, Oregon passed measure 109 – a legislative measure that legalized psilocybin for therapeutic application. Likewise, this news was coupled with the passing of measure 110, which decriminalized small possession of all drugs in general. Taken together, this news shows a remarkably progressive attitude towards drugs and drug usage in Oregon, and we can only hope the rest of the world follows suit.

First Psychedelic

A Terrific Way to Enter 2021

The psychedelic medicine renaissance triumphed above what many have called the worst closer to a decade in modern history. Beyond public health obstacles, the industry overcame financial downfall, which is evident by some of these aforementioned “firsts.” Equally important, 2020 set the stage clinically, which means this well funded machine can now explore even more neuro-based treatments for trauma, addiction, depression, and other psychological issues plaguing society. We look forward to covering all the victories to come in the new year and would like to thank the people who made this previous year possible.

‍

Posted on

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University

The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.

“Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,” said Dr. Polito. “In exploring the experiences of genuine microdosers from multiple angles, looking at behavioural, neuroimaging and biomarker data, we want to discover what actually happens when people microdose ‘in the wild’ and whether we can find objective indicators of some of the benefits that microdosers claim.”

The study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.

“This study will further shed light on currently ambiguous effects of microdosing,” said Josh Bartch, CEO and Co-Founder of Mydecine. “Microdosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, we are helping to build a library of solid data sets that begin to tell us how microdosing works, and how it can be used in future clinical trials for various mental health issues.”

Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University. His focus is on self representation and developing measures of how our sense of self changes in different contexts, clinical conditions, and altered states of consciousness.

About Mydecine Innovations Group

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine’s portfolio companies Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ position the company at the forefront of disruptive modern medicine.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

‍

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

‍

Posted on

Psychedelic Scientist Robin Carhart Harris Leads The Research Renaissance With Over 100 Peer-Reviewed Publications

Published at Microdose

‍

Groundbreaking clinical research has become the bedrock of the modern psychedelic renaissance. One scientist pioneering the way forward in psychedelic and consciousness research is Robin Carhart Harris. Currently the head of the Center for Psychedelic Research at Imperial College London, Carhart-Harris has a remarkable record of academic contributions to the emerging space. Having co-authored over 100 peer-reviewed publications, Carhart-Harris has played a pivotal role in the reinvigoration of psychedelic science. Here are some notable scientific achievements Harris has made towards advancing the psychedelic renaissance.

Carhart Harris Breaking Convention

Using fMRI Technology to Dive Deep Into Psychedelics and Brain Function

The hallmark of Carhart-Harris’s research is his use of functional magnetic resonance imaging (fMRI) to investigate brain function when under the influence of psychedelics. Indeed, fMRI data was at the heart of his 2014 paper The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Likewise, fMRI brought us his 2016 research on the neural correlates of LSD experiences. While psychedelic enthusiasts have always understood that these compounds were special, brain imaging was vital to understanding why they were special, how these drugs derive their therapeutic value, the true potential of these drugs, etc.

Curious how Harris’s work is being utilized in the emerging psychedelic medicine industry? Harris is one of the scientific advisors to Entheon Biomedical, a company using DMT to treat addiction. Read our exclusive story detailing the underlying mechanism behind their approach.

Carhart Harris science

Carhart-Harris Was the First Scientist to Administer LSD to Humans in the UK since 1971

After decades of prohibition, Carhart-Harris conducted revolutionary clinical studies – becoming the first scientist to administer LSD to humans in the UK since 1971, when the Misuse of Drugs Act prevented further administrations. This historic achievement marks a turning point in the evolution of psychedelic science and research. On paper, this moves the clinical community closer to understanding the gnosis of these drugs. But beyond scientific vigor and academic advancement, this moment marks a defiance to previously upheld societal standards. For many outside of the psychedelic community (or simply newer to it), this 2014 moment forced them to reconsider their preconceptions about LSD and perhaps drugs at large.

Carhart Harris science 2

Carhart-Harris Has Received Notable Support From Leading Research Institutions

The Beckley Foundation, Hefter Research Institute, and the Multidisciplinary Association for Psychedelic Studies (MAPS) all vehemently support Dr. Carhart-Harris. He is most commonly applauded for his work with psilocybin and LSD, including his especially celebrated research on psilocybin for treatment-resistant depression. It should no surprise that, beyond collaborations, Harris is a highly anticipated speaker at events hosted by the aforementioned institutions.

Robin Carhart-Harris recently spoke at our latest Mydecine Speaker Series – Psychedelic Solutions virtual event. Learn more about our events here.

carhart harris convos

Saying Thank You to Psychedelic Pioneers This Christmas

Harris will surely continue to push the psychedelic neuroscience Overton window. This Christmas, as you’re with your friends and family (in person or virtually), consider spreading the word of these great psychedelic research efforts. The more we inform our loved ones about these once niche-interests, the more we can build our community, whether that be via event attendance or donating to Imperial College London’s psychedelic research efforts.

‍